This pet care stock is being mispriced and mislabeled by investors. How to trade it using options

Chewy trades at 16.5x forward-adjusted EPS with a ~6.7% free cash flow yield and expected revenue growth >8%, yet sits at ~25% discount to the market forward multiple. The author argues Chewy’s Autoship-driven, habit-based recurring revenue makes pet spending more durable than typical discretionary categories, supported by high gas prices boosting delivery value. Risks: the stock is down 23% YTD and ~78.5% from its Feb 2021 high, and Q4 FY2026 results are due March 25 with high implied volatility; the piece suggests options spreads (e.g., June 20/27.5/32.5) as tactical ways to express the view.

Analysis

Re-labeling risk matters: Chewy’s structural advantage is habit-forming, recurring demand that reduces revenue elasticity to short-term consumer discretionary shocks. That creates a different cash-flow profile than typical online retail — lower churn, higher visibility into unit economics, and a pathway to margin through mix-shift (prescription/private-label/subscription) rather than pure price competition.

Second-order margin drivers and risks are operational, not just top-line. Shipping and last-mile cost inflection from energy or carrier rate resets can swing near-term gross margins materially; conversely, any sustained improvement in autoship penetration or prescription growth compounds operating leverage, turning a middling growth multiple into growth-with-stability multiple expansion within 6–18 months.

Options and flows are now a behavioral governor: elevated implied volatility and a deep technical downtrend mean short-term moves can be flow-driven rather than fundamentals-driven — IV crush on a benign print is as consequential as a miss. That makes defined-risk, event-aware structures preferable to naked directional bets ahead of the print, while a patient post-earnings entry captures the greatest asymmetry if the company demonstrates recurring revenue resiliency.

Catalysts and timelines: days (earnings and IV re-pricing), weeks (post-print institutional repositioning), and quarters (realization of higher-margin mix and LTV/CAC improvements). Tail risks that would reverse the bull case include a persistent loss of pricing power from a larger competitor, a sudden step-up in logistics passthrough costs, or evidence that autoship retention is weakening.

Key Decisions for Investors

• Core position (3–12 months): Buy CHWY equity sized as 1–2% portfolio; hedge with a 3–6 month put spread (buy 1x 6-month at-the-money put, sell 1x further OTM put) to cap downside while leaving upside exposed. R/R: limited defined downside, uncapped upside to multiple re-rating if autoship/prescription mix improves.
• Event-aware option play (days–weeks, pre-earnings): Sell a defined-risk iron-condor/short butterfly expiring the week after earnings to collect elevated IV, sized to max loss = 1–1.5% portfolio. R/R: collect premium; risk if print shocks the market — use hemmed strikes to limit tail gamma.
• Post-earnings asymmetric call spread (6–9 months): If results validate recurring revenue durability, buy a 6–9 month call spread (debit) to leverage re-rating while limiting premium decay; fund partially by selling further-dated OTM calls if comfortable capping upside. R/R: limited cost for leveraged upside capture.
• Relative pair trade (3–12 months): Long CHWY / short XLY (or a broad retail ETF) to isolate pet-care durability vs general discretionary pain. R/R: protects vs sector rebound risk while capturing secular outperformance if pet spend proves non-discretionary.